Education
About Us
Working with TipRanks
Follow Us
Tilray (DE:2HQ0)
XETRA:2HQ0
2HQ0 Stock Chart & Stats
€6.66
--
Market closed
€6.66
--
Day’s Range― - ―
52-Week Range€2.81 - €19.88
Previous CloseN/A
VolumeN/A
Average Volume (3M)4.78K
Market Cap
€751.09M
Enterprise Value€886.55M
Total Cash (Recent Filing)€407.29M
Total Debt (Recent Filing)€446.52M
Price to Earnings (P/E)―
Beta1.23
Next Earnings
Apr 14, 2026EPS Estimate
-0.11Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.35
Shares Outstanding116,506,910
10 Day Avg. Volume3,733
30 Day Avg. Volume4,784
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)0.18
Price to Sales (P/S)0.34
P/FCF Ratio-2.17
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€8.12Price Target Upside21.88% Upside
Rating ConsensusHold
Number of Analyst Covering6
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Strong Revenue GrowthSustained, large top-line expansion signals improving product-market fit and distribution traction across segments. Durable revenue scaling supports operating leverage potential and funds reinvestment, reducing reliance on one-off financing if growth is maintained.
Improved Liquidity / Net CashA materially stronger liquidity position and move to net cash give the company breathing room to execute restructuring, invest in higher‑margin markets, and absorb regulatory delays without immediate refinancing, lowering short‑term funding risk.
Scale In Distribution & MedicalA growing medical business and a deliberate expansion of pharmacy distribution create recurring, higher‑margin channels. Scaling distribution and clinical footprint builds durable, diversified revenue streams less tied to spot retail cannabis pricing.
Bears Say
Weak Cash GenerationPersistent negative operating and free cash flow indicate the business is not yet self‑funding, requiring continued external capital or asset sales. This constrains long‑term investment, increases financing dependency, and elevates dilution or liquidity risk if improvement stalls.
Persistent GAAP Losses & Negative ROEDeep, ongoing GAAP losses and sharply negative ROE reflect value erosion and limited profitability leverage. Over time this weakens the capital base, limits strategic optionality, and pressures ability to fund growth from internal returns absent sustained margin recovery.
Regulatory & Permit UncertaintyStructural regulatory uncertainty—especially potential bans on intoxicating hemp and ongoing permit delays in key markets—can permanently curtail product categories, raise compliance costs, and force strategic shifts, creating multi‑quarter revenue and margin risk.
Tilray News
2HQ0 FAQ
What was Tilray’s price range in the past 12 months?
Tilray lowest stock price was €2.81 and its highest was €19.88 in the past 12 months.
What is Tilray’s market cap?
Tilray’s market cap is €751.09M.
When is Tilray’s upcoming earnings report date?
Tilray’s upcoming earnings report date is Apr 14, 2026 which is in 50 days.
How were Tilray’s earnings last quarter?
Tilray released its earnings results on Jan 08, 2026. The company reported -€0.346 earnings per share for the quarter, missing the consensus estimate of -€0.181 by -€0.165.
Is Tilray overvalued?
According to Wall Street analysts Tilray’s price is currently Undervalued.
Does Tilray pay dividends?
Tilray does not currently pay dividends.
What is Tilray’s EPS estimate?
Tilray’s EPS estimate is -0.11.
How many shares outstanding does Tilray have?
Tilray has 116,506,910 shares outstanding.
What happened to Tilray’s price movement after its last earnings report?
Tilray reported an EPS of -€0.346 in its last earnings report, missing expectations of -€0.181. Following the earnings report the stock price went up 1.883%.
Which hedge fund is a major shareholder of Tilray?
Currently, no hedge funds are holding shares in DE:2HQ0
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Tilray Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
€8.12 (21.88% Upside)
€8.12 (21.88% Upside)
Blogger Sentiment
Neutral
DE:2HQ0 Sentiment 63%
Sector Average ―
Sector Average ―
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-10.68%
12-Months-Change
Fundamentals
Return on Equity
-83.42%
Trailing 12-Months
Asset Growth
-49.94%
Trailing 12-Months
Company Description
Tilray
Tilray Brands, Inc. engages in the research, cultivation, production, marketing, and distribution of medical cannabis products in Canada, the United States, Europe, Australia, New Zealand, Latin America, and internationally. The company operates through four segments: Cannabis Business, Distribution Business, Beverage Alcohol Business, and Wellness Business. It offers medical and adult-use cannabis products, including GMP-certified flowers, oils, vapes, edibles, and topicals; purchases and resells pharmaceutical and wellness products; and produces, markets, sells, and distributes beverage alcohol products, and hemp-based food and other wellness products. The company offers its products under the Tilray, Aphria, Broken Coast, Symbios, B!NGO, The Batch, P'tite Pof, Dubon, Good Supply, Solei, Chowie Wowie, Canaca, RIFF, SweetWater, Breckenridge Distillery, Alpine Beer Company, and Green Flash brands. It sells its products to retailers, wholesalers, patients, physicians, hospitals, pharmacies, researchers, and governments, as well as direct to consumers. The company was formerly known as Tilray, Inc. Tilray Brands, Inc. is headquartered in Leamington, Canada.
2HQ0 Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presented multiple meaningful operational and financial improvements: record quarterly revenue, stronger international cannabis and distribution growth, improved margins in cannabis and distribution, a markedly stronger cash position and a significant reduction in operating cash burn and net loss year-over-year. Key execution risks remain, notably beverage segment underperformance, ongoing GAAP net losses, regulatory uncertainty (particularly U.S. hemp-derived THC) and permit/price pressure in parts of Europe. On balance, management emphasized concrete progress, cost savings, reaffirmed guidance and strategic readiness for regulatory shifts, while acknowledging areas still requiring work.View all DE:2HQ0 earnings summaries2HQ0 Stock 12 Month Forecast
Average Price Target
€8.12
▲(21.88% Upside)
Options Prices
Currently, No data available
---